A carregar...

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt

A phase III clinical trial showed gemcitabine chemotherapy combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib significantly improved overall survival in patients with advanced pancreatic cancer. Therefore, we studied whether addition of gemcitabine to erlotinib...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bartholomeusz, Chandra, Yamasaki, Fumiyuki, Saso, Hitomi, Kurisu, Kaoru, Hortobagyi, Gabriel N., Ueno, Naoto T.
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2011
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3157020/
https://ncbi.nlm.nih.gov/pubmed/21850211
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!